TLR4 and long COVID-19: Low-dose naltrexone is hypothesized to alleviate PASC symptoms through neuroinflammation modulation by antagonizing toll-like receptors 4 on microglia and macrophages, leading to reduced production of pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) and oxidative stress [28, 29].